The gap between 'works in rats' and 'safe and effective in humans' has ended promising compounds before
Thus, GLP-1/FGF21 fusions have the potential, at least in rodents, to provide greater improvements in dyslipidemia than GLP-1R agonists and have the potential to drive greater body weight loss through the energy expenditure mechanism not evident with GLP-1 mono-therapy
BioMed research international , 2013 , 783809
In a similar way, acrolein appears to stimulate oxidative stress damage, producing high levels of ceramide, which is accountable for the incrementation of cytosolic Ca 2+ concentration and, consequently, the eryptosis levels [254]
They may recommend increasing your GLP-1 dose if you are not yet at the maximum, evaluating your diet and physical activity patterns, checking for other conditions affecting blood sugar, or considering whether additional medications might be needed